CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 634 enrolled
Drug / intervention
ALK Grass tabletbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00227279
NCT00227279Phase 3Completed
CompareCT.gov

A Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

ALK-Abelló A/S·interventional·Posted Sep 28, 2005·Updated Jan 29, 2013

In Brief

A Phase 3 clinical trial evaluating ALK Grass tablet for Allergy. Completed, enrolled 634 participants across 1 site.

Detailed Summary

This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergy
CountriesDenmark
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2005
Enrollment StartOct 1, 2004
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 20.8 years ago

Interventions

ALK Grass tabletbiological

Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years